True North Therapeutics is a pioneering biotechnology company founded in 2013 with a mission to selectively inhibit the Complement pathway for diseases of high unmet clinical need. The company's lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North, initially formed in 2013 as a spin-out of iPierian, has received Venture Round investment at 01 January 2018 from Mission BioCapital. This funding is pivotal for the company's innovative approach in tackling high unmet clinical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
01 Jan 2018 |
| Series D | $45.00M | 5 |
|
18 Oct 2016 |
| Series C | $40.00M | 4 |
|
03 Dec 2015 |
| Series B | $35.00M | - | 07 Apr 2015 | |
| Series A | $22.00M | - | 17 Jun 2014 |
No recent news or press coverage available for True North Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.